Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Leukemia

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.leu.2404270PMID 16728981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical Learning Theory

  2021cited by this paper
• Global approach to the diagnosis of leukemia using gene expression profiling

  2007cited by this paper
• Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

  2006cited by this paper
• Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR – how well do they correlate?

  2005cited by this paper
• DNA microarrays in clinical cancer research.

  2005cited by this paper
• hOCT 1 and resistance to imatinib.

  2005cited by this paper
• In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.

  2005cited by this paper
• Pattern robustness of diagnostic gene expression signatures in leukemia

  2005cited by this paper
• Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability

  2005cited by this paper
• The helix–loop–helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers

  2004cited by this paper
• Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α

  2004cited by this paper
• Vanin-1−/− Mice Exhibit a Glutathione-Mediated Tissue Resistance to Oxidative Stress

  2004cited by this paper
• The biology of CML blast crisis.

  2004cited by this paper
• Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib

  2004cited by this paper
• Involvement of Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) in Apoptosis Induced by β-Hydroxyisovalerylshikonin*

  2004cited by this paper
• Endogenous Inhibitors of Nuclear Factor-κB, An Opportunity for Cancer Control

  2004cited by this paper
• Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR.

  2004cited by this paper
• Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages.

  2004cited by this paper
• Endogenous inhibitors of nuclear factor-kappaB, an opportunity for cancer control.

  2004cited by this paper
• Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

  2004cited by this paper
• Clinical resistance to imatinib: mechanisms and implications.

  2004cited by this paper
• Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

  2004cited by this paper
• Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

  2004cited by this paper
• Accuracy of cDNA microarray methods to detect small gene expression changes induced by neuregulin on breast epithelial cells

  2004cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Evaluating Methods for Classifying Expression Data

  2004cited by this paper
• Chipping away at the chip bias: RNA degradation in microarray analysis

  2003cited by this paper
• Molecular mechanisms of transformation by the BCR-ABL oncogene.

  2003cited by this paper
• Chronic myelogenous leukemia molecular signature

  2003cited by this paper
• The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays.

  2003cited by this paper
• Inhibition of caspase-9 activity and Apaf-1 expression in cisplatin-resistant head and neck squamous cell carcinoma cells.

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin

  2003cited by this paper
• A Novel Type of Deubiquitinating Enzyme*

  2003cited by this paper
• Prediction of response to imatinib by cDNA microarray analysis.

  2003cited by this paper
• Within the fold: assessing differential expression measures and reproducibility in microarray assays

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Variance stabilization applied to microarray data calibration and to the quantification of differential expression

  2002cited by this paper
• Chronic myelogenous leukemia: mechanisms underlying disease progression

  2002cited by this paper
• Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays.

  2002cited by this paper
• Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.

  2002cited by this paper
• Interaction between UV-damaged DNA Binding Activity Proteins and the c-Abl Tyrosine Kinase*

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells

  2001cited by this paper
• Gonadotropin-releasing Hormone Receptor-coupled Gene Network Organization *

  2001cited by this paper
• Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

  2001cited by this paper
• Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis.

  2001cited by this paper
• Id1 expression is associated with histological grade and invasive behavior in endometrial carcinoma.

  2001cited by this paper
• The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas.

  2001cited by this paper
• Gonadotropin-releasing Hormone Receptor-coupled Gene Network Organization* 210

  2001cited by this paper
• Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells

  2000cited by this paper
• Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

  1999cited by this paper
• A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M.

  1998cited by this paper
• An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.

  1994cited by this paper
• Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction.

  1993cited by this paper
• A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines

  1980cited by this paper

• Paraoxonase‐2 shRNA‐mediated gene silencing suppresses proliferation and migration, while promotes chemosensitivity in clear cell renal cell carcinoma cell lines

  2024cites this paper
• Contribution of the Paraoxonase-2 Enzyme to Cancer Cell Metabolism and Phenotypes

  2024cites this paper
• The importance of personalized medicine in chronic myeloid leukemia management: a narrative review

  2023cites this paper
• Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice

  2023cites this paper
• Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance

  2023cites this paper
• Feature selection for high dimensional microarray gene expression data via weighted signal to noise ratio

  2023cites this paper
• Copper-Based Metal-Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis.

  2022cites this paper
• The Role of the Thioredoxin Detoxification System in Cancer Progression and Resistance

  2022cites this paper
• RHOA G17V induces T follicular helper cell specification and involves angioimmunoblastic T-cell lymphoma via upregulating the expression of PON2 through an NF-κB-dependent mechanism

  2022cites this paper
• Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

  2021cites this paper
• Human Paraoxonase-2 (PON2): Protein Functions and Modulation

  2021cites this paper
• The key successful factors of video and mobile game crowdfunding projects using a lexicon-based feature selection approach

  2021cites this paper
• Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

  2021cites this paper
• Identification of cancer related genes using feature selection and association rule mining

  2021cites this paper
• A text mining-based framework to discover the important factors in text reviews for predicting the views of live streaming

  2021cites this paper
• PON2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia

  2021cites this paper
• Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

  2021cites this paper
• Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia

  2021cites this paper
• ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo

  2020cites this paper
• sigFeature: Novel Significant Feature Selection Method for Classification of Gene Expression Data Using Support Vector Machine and t Statistic

  2020cites this paper
• Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

  2019cites this paper
• The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia

  2019cites this paper
• Determinants of stem cell enrichment in healthy tissues and tumors: implications for non-genetic drug resistance

  2019cites this paper
• Why Customers Don’t Revisit in Tourism and Hospitality Industry?

  2019cites this paper
• Mast cell activation in the context of elevated basal serum tryptase: genetics and presentations

  2019cites this paper
• Clinical Approach to a Patient with Elevated Serum Tryptase: Implications of Acute Versus Basally Elevated Levels

  2019cites this paper
• Paraoxonase 2 is critical for non-small cell lung carcinoma proliferation.

  2019influential citation
• Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

  2019cites this paper
• Finding the Keywords Affecting the Success of Crowdfunding Projects

  2019cites this paper
• Medical genomics research at BGRS-2018

  2019cites this paper
• The clinical and prognostic significance of paraoxonase-2 in gastric cancer patients: immunohistochemical analysis

  2019cites this paper
• Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer

  2018cites this paper
• Modulating ROS to overcome multidrug resistance in cancer.

  2018cites this paper
• The Keywords of Affecting Performance for Live Streaming

  2018cites this paper
• The role of paraoxonase in cancer.

  2017cites this paper
• Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia

  2017cites this paper
• The interaction of homoserine lactones and paraoxonase 2 modulates cell death signaling and cell proliferation.

  2017cites this paper
• Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

  2016cites this paper
• A Review on Imatinib: A wonder drug in Oncology

  2016cites this paper
• The anti-apoptotic PON2 protein is Wnt/β-catenin-regulated and correlates with radiotherapy resistance in OSCC patients

  2016cites this paper
• A hierarchical two-phase framework for selecting genes in cancer datasets with a neuro-fuzzy system

  2016cites this paper
• Paraoxonase 2 Serves a Proapopotic Function in Mouse and Human Cells in Response to the Pseudomonas aeruginosa Quorum-sensing Molecule N-(3-Oxododecanoyl)-homoserine Lactone*

  2015cites this paper
• Toward an Improved Chronic Myelogenous Leukemia Treatment: Blocking the Stem Cell Factor–Mediated Innate Resistance With Anti–c-Kit Synthetic-Antibody Inhibitors

  2015cites this paper
• SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias.

  2015cites this paper
• A composite gene selection for DNA microarray data analysis

  2015cites this paper
• Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis

  2015cites this paper
• Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias.

  2015cites this paper
• The influence of gene polymorphisms, modifiable lifestyle factors, and toxicants on the protective effects of the paraoxonase genes

  2014cites this paper
• Challenges of Treatment: Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia

  2014cites this paper
• Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib

  2014cites this paper
• Network information improves cancer outcome prediction

  2014cites this paper
• Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?

  2014cites this paper
• Handbook of Chronic Myeloid Leukemia

  2014cites this paper
• myeloid leukemia stem cells Genomic instability may originate from imatinib-refractory chronic

  2013cites this paper
• Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

  2013cites this paper
• Local-learning-based neuron selection for grasping gesture prediction in motor brain machine interfaces

  2013cites this paper
• PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death

  2012cites this paper
• Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems

  2012cites this paper
• Die Regulation des Enzyms Paraoxonase-2 sowie dessen Einfluss auf die Hämatopoese

  2012cites this paper
• Sparse and stable gene selection with consensus SVM-RFE

  2012cites this paper
• The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era.

  2012cites this paper
• Referenzen des Kompetenznetzes „Akute und chronische Leukämien“

  2012cites this paper
• Protectors or Traitors: The Roles of PON2 and PON3 in Atherosclerosis and Cancer

  2012cites this paper
• Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.

  2012cites this paper
• Genomics and cancer drug resistance.

  2012cites this paper
• Gene Expression Profiling in Hematologic Malignancies

  2012cites this paper
• Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

  2012cites this paper
• Molecular Aspects of Hematologic Malignancies

  2012cites this paper
• Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells

  2011influential citation
• with imatinib response in chronic-phase chronic myeloid leukemia patients treated cells to predict major cytogenetic + A gene expression signature of CD34

  2011cites this paper
• Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia

  2011cites this paper
• Mechanisms of resistance to BCR–ABL kinase inhibitors

  2011cites this paper
• Prognostic significance of treatment response in CML in view of current recommendations for treatment and monitoring

  2011cites this paper
• Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.

  2011cites this paper
• Personalized Medicine: Marking a New Epoch in Cancer Patient Management

  2010cites this paper
• Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia

  2010cites this paper
• Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures

  2010cites this paper
• Molecular Cancer esearch ew sonalized Medicine : Marking a New Epoch in Cancer R ient Management

  2010cites this paper
• A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia.

  2010influential citation
• A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

  2010cites this paper
• Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout

  2009cites this paper
• RUNX1T1 is overexpressed in imatinib mesylate-resistant cells.

  2009cites this paper
• Utilizing the molecular gateway: the path to personalized cancer management.

  2009cites this paper
• Role of gene-expression profiling in chronic myeloid leukemia

  2009cites this paper
• The impact of gene profiling in chronic myeloid leukaemia.

  2009cites this paper
• Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients

  2009cites this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cites this paper
• Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

  2009cites this paper
• Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

  2009cites this paper
• Prognostic factors in chronic myeloid leukaemia.

  2009cites this paper
• Cancer drug resistance

  2008cites this paper
• Biomarker discovery across annotated and unannotated microarray datasets using semi-supervised learning

  2008cites this paper
• Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia

  2008cites this paper
• Identification of collapsin response mediator protein‐2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes

  2008cites this paper
• Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

  2008cites this paper
• Milestones and monitoring in patients with CML treated with imatinib.

  2008cites this paper
• BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients

  2008cites this paper
• Expression of CASP9 gene and its polymorphism distribution in colon cancer

  2008cites this paper
• Gene expression profiling in rheumatoid arthritis: current concepts and future directions

  2008cites this paper
• Stem Cell Biomarkers in Chronic Myeloid Leukemia

  2008cites this paper